Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.40 |
| ▸ | GCK | P35557 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL378369 | 0.93 | KMT2A (0.41) | KMT2AMEN1ALDH1A1CREBBPGCK | |
| SCHEMBL148034 | 0.86 | KMT2A (0.43) | KMT2AMEN1ALDH1A1CREBBPGCK | |
| SCHEMBL7532781 | 0.77 | ALDH1A1 (0.49) | KMT2AMEN1ALDH1A1CREBBPHPGD | |
| SCHEMBL7427803 | 0.76 | ALDH1A1 (0.53) | KMT2AALDH1A1CREBBPHPGDKDM4E | |
| SCHEMBL7416386 | 0.74 | ALDH1A1 (0.51) | KMT2AALDH1A1HPGDKDM4ENPC1 | |
| SCHEMBL2236956 | 0.73 | ALDH1A1 (0.50) | KMT2AALDH1A1HPGDKDM4ENPC1 | |
| SCHEMBL7473563 | 0.73 | ALDH1A1 (0.49) | KMT2AALDH1A1HPGDKDM4ENPC1 | |
| SCHEMBL18737831 | 0.71 | ALDH1A1 (0.47) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL13739097 | 0.71 | KMT2A (0.36) | KMT2AMEN1ALDH1A1CREBBPGCK | |
| SCHEMBL20847148 | 0.71 | PTGER4 (0.52) | KMT2AMEN1ALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3431086-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2020-06-17 | — | — | EP | disclosed |
| US-20200129512-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2020-04-30 | — | — | US | disclosed |
| EP-3431086-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | Resverlogix Corp. (CA) | 2019-01-23 | — | — | EP | disclosed |
| EP-2421533-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2018-10-17 | — | — | EP | disclosed |
| US-20170333419-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2017-11-23 | — | — | US | disclosed |
| US-20170326143-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2017-11-16 | — | — | US | disclosed |
| US-9757368-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2017-09-12 | — | — | US | disclosed |
| WO-2013186612-A1 | THE USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BET (BROMODOMAIN AND EXTRA TERMINAL DOMAIN) PROTEINS | RVX THERAPEUTICS INC. (CA) | 2013-12-19 | — | — | WO | disclosed |
| US-20130281398-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-03-08 | — | — | US | disclosed |
| EP-2421533-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010123975-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | KMT2A 3505/4885MEN1 1990/4885ALDH1A1 1042/4885 |
| US-20130281398-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | PHKB, BAZ2A, EP300 | KMT2A 199/4885MEN1 4236/4885ALDH1A1 3920/4885 |
| US-20170326143-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | KMT2A 3505/4885MEN1 1990/4885ALDH1A1 1042/4885 |
| US-20170333419-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | KMT2A 3505/4885MEN1 1990/4885ALDH1A1 1042/4885 |
| US-20200129512-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | KMT2A 3505/4885MEN1 1990/4885ALDH1A1 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.